It is made available under a CC-BY-NC-ND 4.0 International license .

Cross-Sectional Study on Philippine National Insurance Data on Malignancy

Alip S^{1,2,5}, Castillo C⁵, Ong, K., Castro A J^{3,5}, Gonzales K², Gasa G², Fernandez P², Firaza P², Manalaysay F², Semblante C², Sergio S², Prodigalidad J,^{3,4,5}, Macalalag M^{2,3,5}, Arcinas R², and Roque A³

¹ University of the Philippines, College of Medicine
 ² Research Committee, Philippine Urological Association
 ³ Executive Council, Philippine Urological Association
 ⁴ Philippine Society of Urologic Oncologists
 ⁵ Philippine Endourological Society

Abstract

Introduction

The purpose of the Urologic Diseases in the Philippines study is three-fold: to assess the burden of urologic disease in the country in prevalence and incidence, to identify orphan populations or underserved areas where urological care is most needed, and to provide an administrative data registry for which clinical data may be anchored on.

Materials & Methods

The data were then requested from the Corporate Planning Unit of PhilHealth, with the following inclusion parameters: all beneficiaries (members and their dependents) with a hospital claim in the years 2011 to 2021 with the following primary or secondary diagnoses e following variables: age, sex, admission date, outpatient/inpatient classification, specific illness code, claim amount, claim status, region and type of facility. Prevalence and incidence data were computed considering a 2-year lookback period. Health claims data is limited by limited clinical information it contains, and the selection bias of patients in frequent contact with the healthcare system.

Results

More than 30,000 health claims were reviewed. Incidence data for 2020, in comparison with the Globocan model is as follows: kidney cancer incidence (Philhealth 371 cases, Globocan model 2211) bladder cancer (Philhealth 261 cases, Globocan model 1,541), prostate cancer incidence (Philhealth 934, Globocan model 7,290), testicular cancer incidence (Philhealth 129, Globocan model 355), and penile cancer incidence (Philhealth 32, Globocan model 114). Other information such as prevalence data, regional and facility-type data are contained in the tables and supplementary material. Disparities in reporting may be due to remediable logistical and reporting issues, RVS and ICD exclusivity, and low service utilization.

Conclusion

Incidence across cancer types follow the trend of global estimates, with prostate cancer being the most prevalent, followed by kidney, bladder, testis, and penile cancers. For future studies, it is imperative that administrative and clinical data linkages are established to form a more holistic picture of the urologic disease burden in the country.

Introduction

A broad tally of urologic diseases in the Philippines is necessary. As in most countries, available healthcare data is highly fragmented.¹ Three major types of data sources are available to inform health research: clinical care data (including electronic health records, hospital or clinic-based datasets), large-scale administrative data (national insurance claims data, pharmaceutical data, government agency data), and clinical trial data (both publicly and privately funded). Access to administrative and clinical data, including linkages among them must be leveraged; opportunities to make data accessible at point of care for decision-making and health policy must be sought.

The purpose of the Urologic Diseases in the Philippines study is three-fold: to assess the burden

It is made available under a CC-BY-NC-ND 4.0 International license .

of urologic disease in the country in prevalence and incidence, to identify orphan populations or underserved areas where urological care is most needed, and to provide an administrative data registry for which clinical data may be anchored on. The project is intended to be in several parts, each published separately as a rolling summary of the entirety of the project. The first part investigates the adequacy of a single national insurance claims database to inform urologic cancer epidemiology. The data from the Philippine Health Insurance Corporation (Philhealth) are meant to complement existing clinical data from cancer registries, and hospital data from the foremost urological training institutions.

There is no perfect database, and comprehensiveness is most often sacrificed for accessibility and ease of use. Currently, there are four subnational cancer registries in the Philippines that sample Manila, Rizal, Cebu, and Davao.² Most Philippine data in global cancer catalogs, such as in the World Health Organization's Global Cancer Registry, use statistical modeling for countries like the authors' that lack a robust national registry, combining subnational data from the four registries and projections based on neighboring Southeast Asian countries.

Despite many arguable flaws and gaps in policy, it is high time that one of the strengths of the Universal Healthcare Act and national health insurance policy be utilized – that of universal enrolment and coverage, to gather a real-world estimate of healthcare utilization for cancer and other diseases. After the ratification of the Universal Healthcare Act (RA11223) in July of 2018, all Filipinos are now automatically included under the National Health Insurance Program, with coverage approaching 90% of the population.³

Limitations of the Study

Using a single database of administrative data is fraught with inherent limitations. Firstly, there is an inherent bias in administrative data toward individuals who use health services. Secondly, the unit of analysis is a health claim (a clinic visit, admission, or contact with healthcare service), not individual patients. This data must be aggregated and disaggregated accordingly. Factors related to the natural history of the disease, such as disease recurrence, upstaging or morbidity, are impossible to generate. Thirdly, the usefulness of healthcare claims analyses can be complicated by incomplete health claims, unreliable or invalid coding, and missing information, such as important clinical variables. Diagnoses are often listed in the medical record; however, the principal diagnoses may not be cited accurately when the health claim is filed.

Specific limitations of this study include: a lack of direct supervision by primary or coinvestigators of the Philhealth database: data are requested from the Philhealth representative in charge of searching and disaggregation and is forwarded to the investigators in a limited columnar file. Investigators did not have access to personal beneficiary data and no identifying patient information were released. Also, patient admissions recorded as 'procedure only' are captured by Relative Value Scale (RVS) code (not ICD code) and were not included in the study. Lookback capture was used to compensate for this underreporting.

Researchers dealing with a large volume of health claims information are always in an unsatisfactory position of having no definitive gold standard against which to validate administrative data.⁴ However, a prime advantage, of working with claims data is not only in

It is made available under a CC-BY-NC-ND 4.0 International license .

quantifying the burden of disease, but in also defining a population for whom processes and outcomes of disease management may be explored. This is especially valuable in evaluating delivery and outcomes of care. Also, national databases mirror real-world data in that they reflect medical sociology and recording practices under economic constraints.⁵

As the recognized limitations of a claim or insurance-based databases are manifold, the authors' fervent hope is to pave the way for more tailored, integrative, and accessible databases that may be relied upon by doctors and researchers alike.

Materials and Methods

Database Selection and Data Acquisition

In preparation for data collection and aggregation, a literature review of all existing studies on Philhealth-sourced data and concomitantly published datasets was done on Pubmed, HERDIN, and pre-print servers. No available datasets were identified. Local full texts articles, as well as Philhealth policy briefs and public releases were reviewed for information on unified Philhealth process flows. The research was registered under DOH-PHCRD Registration number PHRR220211-004331. The study procedures are in accordance with ICH-GCP principles, the provisions of the National Ethical Guidelines for Health and Health-related Research of 2017, and the Data Privacy Act of 2012 (RA 10173)

The data were then requested from the Corporate Planning Unit of PhilHealth, with the following inclusion parameters: all beneficiaries (members and their dependents) with a hospital claim in the years 2011 to 2021 with the following primary or secondary diagnoses: ICD-10 Codes (International Classification of Disease 10th Edition) C60 malignant neoplasm of the penis, C61 malignant neoplasm of the prostate, C62 malignant neoplasm of the testis, C64 malignant neoplasm of the kidney, C67 malignant neoplasm of the bladder. ICD-10 coding was used as the 10th edition coding is the current coding practice and has been for the inclusive sample years. Data retrieved from PhilHealth included the following variables: age, sex, admission date, outpatient/inpatient classification, specific illness code, claim amount, claim status. For patients with prostate cancer, data was further refined to include the following additional variables: region, and type of facility.

The patients are identified using a study-dedicated (anonymized) pseudo-identification number. Investigators had no access to identifying patient information. Each entry represented a single clinic visit. For instance, patients with multiple clinic visits were listed with the same pseudo-ID under multiple entries, with each entry representing each visit. Patients are unrestricted in their access to clinics, specialists, and hospitals. Thus, it is plausible for multiple claims to be made on the same day in a different clinic setting, or during multiple monthly visits to a single clinic. The first claim was chosen to define incidence. A disease-free interval of > 2 years was considered significant.

Denominators were taken from Philhealth annual reports and were verified through Philhealth correspondence. Philhealth releases public use data sets in one-year cycles. Gendered

It is made available under a CC-BY-NC-ND 4.0 International license .

denominators for male genitourinary cancers were also supplied and refined by the Corporate Planning Unit.

Statistical Analysis and the Lookback Period

Administrative claims data are heavily left and right censored. Proper selection of observable person time lends accuracy to estimates of prevalence and incidence, especially of chronic conditions. In this study, observable person-time was defined by enrollment in the claims database. Most contemporary studies on health claims utilize a lookback time to surveil the existing disease.^{5–7} Lookback periods should enable researchers to identify and exclude recurrent cases and increase the accuracy of the incidence estimation.⁶ If the condition of interest, in this study's case cancer – a chronic condition, is observed to occur during the lookback time, then it is a prevalent disease. If the condition of interest is not observed to occur in the lookback time but does occur over the period of interest, then this case may be considered incident.⁵ The choice of lookback interval was critical to the analysis, and was defined as two years in this study, similar to previous studies on lookback for cancer.⁸

In this study, the denominator was the complete-period population or the number of beneficiaries (members and dependents eligible to claim) for the year of interest. Health claims data analysis involves calculation of diagnosis prevalence or incidence with the number of people with the primary diagnosis as the target illness, divided by the number of people covered by the health plan and not by those who have registered a health claim.⁹

All claims and health visits were aggregated under each unique patient identification number. That is to say, multiple visits of the same patient were aggregated under that patient and counted as one case under the first incident year. Frequency was used to described demographics of patients included in the study. Prevalence and incidence with their corresponding confidence intervals were calculated using the STATA software (command cii proportions) (StataCorp LLC, Texas, USA). Full operational definitions and formulae are available as supplementary material.

It is made available under a CC-BY-NC-ND 4.0 International license .

Results

Table 1 shows the total registered Philhealth beneficiaries per year as a percentage of the Philippine National Statistics Authority population estimate. All Filipinos are automatically included under the National Health Insurance Program, registered beneficiaries are taken to mean qualified members based on entitlement. Beneficiaries include all registered members and dependents, regardless of premiums paid. It also shows total male beneficiaries, which served as total population-at-risk for prostate, testicular, and penile cancer. All membership categories are included in the count. Qualified dependents are declared by members and are similarly entitled to benefit availment.³

The sudden increase in total male beneficiaries from 2013 to 2014 is due to the lack of sex-specific data in the earlier years for beneficiaries under categories including Citizen of Other Countries, Enterprise Owner, Family Driver, Filipino with Dual Citizenship, Government, Indigent, Informal Sector, *Kasambahay*, Naturalized Filipino Citizen, Organized Group, Sponsored. Although Philhealth started electronic claims processing in 1995, the electronic database was revamped in 2012 to accommodate the new payment mechanism.¹⁰ Subsequently, better data capture is apparent. Thus, for the years 2011-2013, the population-based estimate (with the respective coverage percentage applied) was used as the population-at-risk denominator instead (shown as a parenthetical in the corresponding rows).

The increase in coverage from 2017 to 2018 was due to the ratification of the Universal Health Care Act into law. Philippine national health insurance coverage is similar to, if not better than, neighboring countries of similar economic standing, such as Indonesia, which reported 75% coverage in 2018, and Vietnam, which reported 84% coverage in 2017¹⁰

Year	Total Registered Beneficiaries (Percentage	of Total Male Beneficiaries
	Populatio	n)
2011	78,390,000 (82.0)	%) 14,702,032 (*39,222,568)
2012	80,920,000. (84.3)	%) 15,834,192 (*41,040,780)
2013	76,900,000. (78.7)	%) 16,945,352 (*38,984,123.7)
2014	86,224,256. (86.6)	%) 44,403,501
2015	93,445,053. (92.1)	%) 47,814,214
2016	93,400,861 (90.9	%) 47,960,271
2017	96,973,681 (92.8)	%) 46,307,729
2018	104,488,979 (98.8)	%) 51,486,361
2019	97,750,573. (90.4)	%) 46,681,095
2020	95,999,756 (87.3)	%) 46,024,677
2021	98,030,269. (88.9)	%) 45,746,463

Table 1. Total Number of Registered Philhealth Beneficiaries

* based on the National Statistics Authority Population Estimate and Philhealth coverage for the year

It is made available under a CC-BY-NC-ND 4.0 International license .

Kidney Cancer



Figure K1. Distribution of kidney cancer patients from the 2011-2021 Philhealth database

A total of 3,729 unique patients were recorded in the Philhealth dataset where 392 patients had at least two different claim years (multiple patient visits). (Figure K1)

On the average, there were twice more male patients than females. Kidney cancer was most prevalent in 2019 followed by 2018 and 2017. The visits were also prevalent in the 40-59 age group and the patients were mostly males. (Table K1)

Excluded records with mistakes in recording (such as age, Figure K1) were usually part of denied claims.

Table K1 shows kidney cancer prevalence per year. As previously noted, prevalence is taken as the number of cases occurring in the year of interest, and the preceding two years (lookback period). Table K2 shows kidney cancer incidence per year. Incidence is taken as the number of new cases occurring in the year of interest. These cases are preceded by a disease-free period in the entirety of the two-year lookback period.

Paid claims prevalence and incidence (denied and processing claims subtracted from total filed claims), and raw data without lookback periods are shown in Supplementary Tables 1 through 3. Incidence and prevalence rates across years are shown in Supplementary Table 4.

	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
					F	requency					
Total	229	520	789	889	999	1,151	1,233	1,249	1,251	1,229	1,115
Age, years											
≤19	37	83	129	138	170	191	223	216	228	225	225
20-39	14	24	41	47	57	59	61	58	63	65	63
40-59	70	155	248	289	311	356	370	401	395	395	350
60-69	52	141	200	251	285	341	355	334	330	311	292
≥70	56	117	171	164	176	204	224	240	235	233	185
Sex											
Male	154	334	520	584	631	713	773	811	805	757	671
Female	75	186	269	305	368	438	460	438	446	472	444

Table K1. Prevalent Kidney Cancer Cases Per Year Based on Filed Claims Within Period of Interest and Lookback Period

Table K2. Incident Kidney Cancer Cases Per Year Based on Filed Claims Within Period of Interest

	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
					F	requency					
Total	229	291	269	298	395	424	388	389	417	371	284
Age, years											
≤19	37	46	46	40	80	62	72	62	75	73	62
20-39	14	10	17	20	21	17	21	18	23	23	15
40-59	70	87	93	100	104	142	117	133	131	114	95
60-69	52	88	59	95	119	122	110	96	112	95	76
≥70	56	60	54	43	71	81	68	80	76	66	36
Sex											
Male	154	180	186	197	222	270	265	249	251	223	168
Female	75	111	83	101	173	154	123	140	166	148	116

It is made available under a CC-BY-NC-ND 4.0 International license .

Bladder Cancer



Figure B1. Distribution of bladder cancer patients from the 2011-2021 Philhealth database

A total of 2,974 unique patients were recorded in the Philhealth dataset where 176 patients had at least two different claim years (multiple patient visits). (Figure B1)

On the average, there were twice more male patients than females. Bladder cancer was most prevalent during 2017-2019. The visits were also prevalent in the older age group and the patients were mostly males. (Table B1) An unspecified bladder location was reported most often, followed by the trigone, and the internal urethra.

Excluded records with mistakes in recording (such as age, Figure 2) were usually part of denied claims.

Table B1 shows bladder cancer prevalence per year. As previously noted, prevalence is taken as the number of cases occurring in the year of interest and the preceding two years (lookback period). Table B2 shows bladder cancer incidence per year. Incidence is taken as the number of new cases occurring in the year of interest. These cases are preceded by a disease-free period in the entirety of the two-year lookback period.

Paid claims prevalence and incidence (denied and processing claims subtracted from total filed claims), and raw data without lookback periods are shown in Supplementary Tables 5 through 7. Incidence and prevalence rates across years are shown in Supplementary Table 8.

	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
					F	requency					
Total	202	388	593	661	779	933	1,022	1,064	1,059	960	833
Age, years											
≤19	2	2	3	6	16	19	16	9	5	7	8
20-39	6	10	20	24	39	42	42	33	32	35	30
40-59	47	93	144	154	176	204	227	235	240	221	209
60-69	56	109	162	193	214	279	306	335	332	312	279
≥70	91	174	264	284	334	389	431	452	450	385	307
Cov											
Male	1/13	281	100	470	552	650	71/	728	731	670	581
Female	59	107	422	191	227	274	308	336	328	290	252
i cinaio	00	107	17.1	101		214	000	000	020	250	202
Cancer subtype											
Malignant neoplasm of anterior wall of bladder	2	2	3	4	6	8	6	6	5	6	5
Malignant neoplasm of bladder	3	8	10	13	14	18	15	13	10	9	10
neck; malignant neoplasm of											
internal urethral orifice											
Malignant neoplasm of bladder,	190	369	569	618	720	848	943	985	983	888	753
unspecified											
Malignant neoplasm of dome of	1	1	2	5	7	11	9	7	5	4	6
bladder			-	_							
Malignant neoplasm of lateral wall of bladder	1	1	2	5	6	11	10	15	14	14	13
Malignant neoplasm of	3	4	4	5	7	7	5	5	8	7	5
overlapping lesion of bladder											
Malignant neoplasm of posterior	2	2	2	0	0	0	0	0	0	0	0
wall of bladder											
Malignant neoplasm of trigone	3	4	6	21	33	45	41	33	34	31	39
of bladder											
Malignant neoplasm of urachus	2	3	4	3	5	5	5	6	7	8	6
Malignant neoplasm of ureteric	0	2	6	6	4	2	3	5	8	9	14
orifice											

Table B1. Prevalent Bladder Cancer Cases Per Year Based on Filed Claims Within Period of Interest and Lookback Period

	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
					F	requency					
Total	202	186	205	254	298	364	350	332	349	260	197
Age vers											
	2	0	1	4	11	4	1	2	1	4	3
519	2	0	1			1	1	2	-	,	-
20-39	6	4	10	10	18	13	10	10	12	10	7
40-59	47	46	51	50	68	80	79	70	83	63	58
60-69	56	53	53	83	73	118	111	104	115	89	69
≥70	91	83	90	107	128	149	149	146	138	94	60
Sex											
Male	143	138	141	179	215	254	238	223	253	183	125
Female	59	48	64	75	83	110	112	109	96	77	72
Cancer subtype											
Malignant neoplasm of anterior	2	0	1	3	2	3	1	2	2	2	1
wall of bladder											
Malignant neoplasm of bladder	3	5	2	6	6	6	3	4	3	2	5
neck; malignant neoplasm of											
internal urethral orifice											
Malignant neoplasm of bladder,	190	179	200	222	275	332	326	309	320	240	167
unspecified		•			<u> </u>	-	<u>^</u>	<u>^</u>	•	4	•
Malignant neoplasm of dome of	1	0	1	4	2	5	2	0	3	1	2
bladder Malianaut na anlann af latanl	4	0	4	4	4	0	2	0	r	2	-
wall of bladder	I	0	I	4	I	0	3	0	5	3	5
Malignant peoplasm of	3	1	0	1	3	0	2	3	3	1	1
overlapping lesion of bladder	5		0	т	0	0	L	0	0	1	I
Malignant peoplasm of posterior	2	0	0	0	0	0	0	0	0	0	0
wall of bladder	2	0	0	0	0	0	0	0	0	0	0
Malignant neonlasm of trigone	3	1	2	18	13	14	14	5	15	11	13
of bladder	Ū		2	10	10			0	10		10
Malignant neoplasm of urachus	2	1	1	1	2	2	1	3	3	2	0
Malignant neoplasm of ureteric	0	2	4	0 0	0	2	1	2	5	2	7
orifice	-	-	-	-	-	-		-	-	-	

Table B2. Incident Bladder Cancer Cases Per Year Based on Filed Claims Within Period of Interest

It is made available under a CC-BY-NC-ND 4.0 International license .

Testicular Cancer



Figure T1. Distribution of testicular cancer patients from the 2011-2021 Philhealth database

A total of 1,213 unique patients were recorded in the Philhealth dataset where 106 patients had at least two different claim years. Excluded records with mistakes in recording (such as age) were usually part of denied claims. (Figure T1)

Considering a 2-year lookback, the years where testicular cancer has the most claims were on 2018 to 2020. (Table T1))

Table T1 shows testicular cancer prevalence per year. As previously noted, prevalence is taken as the number of cases occurring in the year of interest, and the preceding two years (lookback period). Table T2 shows testicular cancer incidence per year. Incidence is taken as the number of new cases occurring in the year of interest. These cases are preceded by a disease-free period in the entirety of the two-year lookback period.

Paid claims prevalence and incidence (denied and processing claims subtracted from total filed claims), and raw data without lookback periods are shown in Supplementary Tables 9 through 11. Incidence and prevalence rates across years are shown in Supplementary Table 12

	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
					F	requency					
Total	63	133	196	235	286	332	392	438	461	440	402
Age, years											
≤19	15	32	44	61	74	97	119	124	135	131	126
20-39	31	60	85	90	113	136	157	188	185	185	172
40-59	14	35	53	62	70	69	81	80	93	85	82
60-69	3	5	10	13	18	19	19	25	24	23	13
≥70	-	1	4	9	11	11	16	21	24	16	9

Table T1. Prevalent Testicular Cancer Cases Per Year Based on Filed Claims Within Period of Interest and Lookback Period

Table T2. Incident Testicular Cancer Cases Per Year Based on Filed Claims Within Period of Interest

	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
					F	requency					
Total	63	70	63	94	115	115	154	157	134	129	125
Age, years											
≤19	15	17	12	29	29	37	50	37	41	43	39
20-39	31	29	25	33	49	51	54	73	50	55	60
40-59	14	21	18	21	28	17	34	27	31	24	23
60-69	3	2	5	6	6	7	6	12	6	5	2
≥70	-	1	3	5	3	3	10	8	6	2	1

It is made available under a CC-BY-NC-ND 4.0 International license .





Figure PE1. Distribution of penile cancer patients from the 2011-2021 Philhealth database

A total of 269 unique patients were recorded in the Philhealth dataset where 15 patients had at least two different claim years. (Figure PE1)

Considering a 2-year lookback, the year where penile cancer has the most claims was on 2020 followed by 2019 and 2017. (Table PE2)

Table PE1 shows penile cancer prevalence per year. As previously noted, prevalence is taken as the number of cases occurring in the year of interest, and the preceding two years (lookback period). Table PE2 shows penile cancer incidence per year. Incidence is taken as the number of new cases occurring in the year of interest. These cases are preceded by a disease-free period in the entirety of the two-year lookback period.

Paid claims prevalence and incidence (denied and processing claims subtracted from total filed claims), and raw data without lookback periods are shown in Supplementary Tables 13 through 15. Incidence and prevalence rates across years are shown in Supplementary Table 16

	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
					F	requency					
Total	12	28	47	60	76	82	89	84	99	100	88
Age, years											
≤19	-	-	-	-	-	-	-	-	-	-	-
20-39	3	3	6	8	11	10	11	10	14	15	14
40-59	5	13	25	34	43	43	46	47	52	55	46
60-69	1	5	7	9	13	14	18	14	20	17	17
≥70	3	7	9	9	9	15	14	13	13	13	11

Table PE1. Prevalent Penile Cancer Cases Per Year Based on Filed Claims Within Period of Interest and Lookback Period

Table PE2. Incident Penile Cancer Cases Per Year Based on Filed Claims Within Period of Interest

	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
					F	requency					
Total	12	16	19	23	30	28	30	26	38	32	16
Age, years											
≤19	-	-	-	-	-	-	-	-	-	-	-
20-39	3	-	3	4	4	2	5	3	5	7	2
40-59	5	8	12	13	16	13	16	18	17	20	9
60-69	1	4	2	3	6	5	7	2	10	3	4
≥70	3	4	2	3	4	8	2	3	6	2	1

It is made available under a CC-BY-NC-ND 4.0 International license .

Prostate Cancer



Figure PR1. Distribution of prostate cancer patients from the 2011-2021 Philhealth database

A total of 10,910 unique patients were recorded in the Philhealth dataset where 1,289 patients had at least two different claim years. (Figure PR1)

Considering a 2-year lookback, the years where prostate cancer has the most claims were on 2017 to 2019. (Table PR1) Most claims originate from NCR, followed by Central Luzon, Central Visayas, and Western Visayas. Most claims are from inpatients, seen at a tertiary or a secondary hospital.

Table PR1 shows testicular cancer prevalence per year. As previously noted, prevalence is taken as the number of cases occurring in the year of interest, and the preceding two years (lookback period). Table PR2 shows kidney cancer incidence per year. Incidence is taken as the number of new cases occurring in the year of interest. These cases are preceded by a disease-free period in the entirety of the two-year lookback period.

Paid claims prevalence and incidence (denied and processing claims subtracted from total filed claims), and raw data without lookback periods are shown in Supplementary Tables 17 through 19. Incidence and prevalence rates across years are shown in Supplementary Table 20

	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
					F	requency					
Total	874	1,717	2,530	2,677	3,032	3,401	3,684	3,856	3,925	3,646	3,016
Age, years											
≤19	1	4	6	8	7	3	3	1	2	2	2
20-39	7	12	16	10	9	4	7	5	7	4	5
40-59	79	151	231	250	268	282	295	325	327	332	281
60-69	252	494	754	790	897	978	1,086	1,142	1,182	1,107	945
≥70	535	1,056	1,523	1,619	1,851	2,134	2,293	2,383	2,407	2,201	1,783
Outpatient											
No	824	1,546	2,238	2,442	2,895	3,387	3,674	3,838	3,903	3,622	3,002
Yes	50	171	292	235	137	14	10	18	22	24	14
Region											
NCR	253	523	785	815	838	855	883	947	965	843	647
I – Ilocos	58	112	176	198	239	265	285	286	328	333	297
II – Cagayan	38	60	90	85	111	127	146	150	150	162	138
III – Central Luzon	77	155	232	241	259	283	324	350	357	334	261
IV-A - CALABARZON	46	85	123	130	159	190	208	211	221	194	173
IV-B – MIMAROPA	38	73	113	122	146	159	172	182	186	177	151
V – BICOL	27	47	68	71	98	124	134	141	144	161	145
VI – Western Visayas	79	150	193	199	231	279	308	313	333	323	290
VII – Central Visayas	110	212	304	285	293	322	349	376	352	329	279
VIII – Eastern	7	21	32	47	68	91	108	124	132	128	95
Visayas											
IX – Zamboanga	14	30	37	57	65	87	92	92	92	74	60
Peninsula											
X – Northern	28	51	83	105	151	188	198	200	201	184	147
Mindanao											
XI – Davao Region	51	89	129	143	167	188	173	180	168	149	105
XII - Soccsksargen	18	43	67	69	90	109	145	154	156	137	120

Table PR1. Prevalent Prostate Cancer Cases Per Year Based on Filed Claims Within Period of Interest and Lookback Period

	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
_					F	requency					
CAR	18	46	72	79	78	85	109	107	96	75	67
ARMM	-	1	2	4	4	3	2	1	2	3	3
CARAGA	8	13	18	22	33	44	46	38	39	37	38
UNKNOWN	4	6	6	5	2	2	2	4	3	3	-
Class											
Ambulatory surgical	-	-	9	8	8	2	1	2	1	1	-
clinic											
Infirmary / dispensary	11	24	42	34	25	14	25	29	25	15	8
Level 1	131	243	374	417	510	589	655	665	683	686	640
Level 2	279	512	742	820	1,042	1,257	1,377	1,425	1,453	1,368	1,172
Level 3	449	932	1,357	1,393	1,445	1,537	1,624	1,731	1,760	1,573	1,196
Unknown	4	6	6	5	2	2	2	4	3	3	-

Table PR1. Prevalent Prostate Cancer Cases Per Year Based on Filed Claims Within Period of Interest and Lookback Period

Table PR2. Incident Prostate Cancer Cases Per Year Based on Filed Claims Within Period of Interest

	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
					F	requency					
Total	874	843	813	923	1,142	1,199	1,216	1,251	1,230	934	655
Age, years											
≤19	1	3	2	2	2	0	1	0	1	1	0
20-39	7	3	6	0	3	0	3	1	2	1	2
40-59	79	73	81	87	87	96	105	121	97	110	64
60-69	252	244	262	264	327	346	380	363	370	296	221
≥70	535	520	462	570	723	757	727	766	760	526	368
Outpatient											
No	824	724	692	921	1,137	1,196	1,215	1,239	1,223	931	652
Yes	50	119	121	2	5	3	1	12	7	3	3

	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
					Fi	requency					
NCR	253	266	264	264	260	291	289	319	296	174	133
I – Ilocos	58	56	64	74	92	90	96	86	125	104	52
II – Cagayan	38	23	29	24	49	48	45	52	44	54	29
III – Central Luzon	77	78	76	77	98	102	118	121	105	88	52
IV-A - CALABARZON	46	39	36	48	67	69	67	68	75	38	48
IV-B – MIMAROPA	38	35	37	39	59	53	54	61	60	41	40
V – BICOL	27	20	21	28	46	46	40	48	44	58	35
VI – Western Visayas	79	71	45	77	96	97	106	90	116	93	59
VII – Central Visayas	110	102	94	76	99	123	106	120	101	86	72
VIII – Eastern	7	13	11	22	35	33	36	50	41	30	19
Visayas											
IX – Zamboanga	14	16	6	33	24	29	35	22	27	19	12
Peninsula											
X – Northern	28	23	31	48	68	67	61	68	63	45	34
Mindanao											
XI – Davao Region	51	40	40	62	61	60	51	64	45	34	16
XII - Soccsksargen	18	24	25	18	43	40	58	47	44	39	29
CAR	18	28	27	18	27	35	42	23	27	19	14
ARMM	-	1	1	2	1	-	1	-	1	2	-
CARAGA	8	5	5	12	16	15	11	9	16	10	11
UNKNOWN	4	3	1	1	1	1	-	3	-	-	-
Class											
Ambulatory surgical	-	-	9	1	-	1	-	1	-	-	-
clinic											
Infirmary / dispensary	11	11	17	2	4	7	12	8	4	3	1
Level 1	131	110	131	159	200	201	226	205	217	219	164
Level 2	279	239	226	323	446	442	447	455	462	367	274
Level 3	449	480	429	437	491	547	531	579	547	345	216
Unknown	4	3	1	1	1	1	-	3	-	-	-

Table PR2. Incident Prostate Cancer Cases Per Year Based on Filed Claims Within Period of Interest

It is made available under a CC-BY-NC-ND 4.0 International license .

Discussion

Data Sources and Comparisons

At present there are four cancer registries in the Philippines, the Department of Health – Rizal Cancer Registry (DOH-RCR) with its catchment area totaling 1343 square kilometers; the Philippine Cancer Society – Manila Cancer Registry (PCS-MCR) with a total land catchment area of 266.5 square kilometers; the Cebu Cancer Registry with a catchment area of 793 square kilometers; and the Davao Cancer Registry with a catchment area estimate of 2,211.3 square kilometers.¹¹ The former two registries have been the main source of cancer incidence data for more than three decades.²

The Global Cancer Observatory (Globocan), is a regular publication of worldwide cancer statistics by the International Agency for Research on Cancer (IARC), which is the specialized cancer agency of the World Health Organization. Globocan 2020 incidence figures for the Philippines extrapolate from the 2017 average of the three of the four abovementioned subnational registries (Cebu Cancer Registry, Manilla Cancer Registry, Rizal Cancer Registry) using prediction models, as historical Philippine cancer incidence data does not exist, and mortality data is not available.¹²

The Global Cancer Observatory publication for 2020 data includes the population-weighted average for incidence rates of the top five cancers in males and top five cancers in females in the Philippines. Prostate cancer in the third most incident cancer in males, the fifth most common overall for both sexes. For mortality data, cancer-specific data is not available, and incidence:mortality ratios are derived from cancer registry data in neighboring countries through modelling.¹² Similarly, prevalence ratios use data from Nordic countries and are scaled using Human Development Index (HDI) ratios.

2020 Globocan Annual Incidence for prostate cancer is at 7,290, kidney at 2,211, bladder at 1,541, testis at 355, and penile at 114.¹² Using cancer registry data, 2008 age-standardized national incidence of prostate cancer was 10.1 per 100,000 with the highest incidence rates in Quezon City, Paranaque, and Manila.²

On the other hand, Philhealth reports its coverage to be 90% of the entire population.³ Prior to 2018, Philhealth has publicly reported its coverage rate or entitlement rate based on premium payments. With the Universal Healthcare Act taking effect, current 'registered members' (the aforementioned 90%) are those already listed in the Philhealth database, having contact with the healthcare system, having secured their Member Data Record and Philhealth ID. To reiterate, unlike claims in Medicare or Medicaid of the United States which covers a certain group of individuals such as the elderly or the indigent population, the Philhealth insurance service has aimed to enroll 100% of the population. This representativeness and comprehensiveness afford us research opportunities not feasible using RCTs or single or oligo-institution databases (clinical data)¹³

Rather than viewing them as independent sources of data, administrative data and clinical registry data are often taken to complement each other to form a more holistic picture of the burden of

It is made available under a CC-BY-NC-ND 4.0 International license .

illness. This has been done in various countries, such as the Medicare-SEER collaboration in the United States.⁹ Taking kidney cancer as an example, Philhealth data reports a 2020 incidence of 371 cases, while the Globocan estimate through registry extrapolation and modeling is pegged at 2211 cases.¹² This five-fold difference reflects data loss from underreporting if the modeling estimates are taken as a gold standard. The underreporting may be due to remediable logistical issues: offline database status, deferral of Philhealth filing due to time or manpower constraints, neglect, and non-compliance. These errors are addressed by monitoring, incentives, and sanctions imposed by Philhealth, as part of institutional protocols.

The results expose one critical methodological limitation of this study. This is its failure to account for cases discharged as RVS (relative value scale) "procedure only" cases that are not co-listed under their respective ICD diagnosis. In its eschewing of the Fee for Service system, in favor of case rate payments in 2013, RVS and ICD classifications pathways are mutually exclusive, except for when claiming two case rates. The latter exceptions are subject to approval, and the more likely scenario is that claims are listed as either medical or procedural only.^{14,15} However, analysis is not as simple as merely including and adding these RVS cases. To illustrate, the RVS code for 'cystoscopy, transurethral resection of bladder tumor' may include benign cases. Conversely, RVS codes for 'cystoscopy' may include bladder cancer patients undergoing surveillance treatment. Clinical data – contained in dedicated registries – may be necessary to correctly classify cases. Future meticulously designed long-term studies are needed to address this data loss. Furthermore, standardization of treatment algorithms and respective reporting must be implemented, disseminated and adhered to by urologists.

Similar differences are seen across all cancers' annual incidence: Bladder cancer (Philhealth 261 cases vs Globocan model 1,541), prostate cancer (Philhealth 934 vs Globocan model 7,290), testicular cancer (Philhealth 129 vs Globocan model 355), and penile cancer (Philhealth 32 vs Globocan model 114).

This study can also be viewed from the perspective of service utilization. In contrasting the Philippine estimate of cancer incidence in the global model to the number of those who enter the Philhealth system and avail themselves of healthcare services, the gap is largely apparent. Primarily due to factors already mentioned, but no doubt partly due to poor *de facto* access to government services in areas where awareness of Philhealth has yet to be reinforced.

Conclusion

Claims analysis of urologic cancers may offer a reasonable estimate to guide service allocation. Incidence across cancer types follow the trend of global estimates, with prostate cancer being the most prevalent, followed by kidney, bladder, testis, and penile cancers. However, underreporting is inherent when the ICD inclusion criteria is applied alone. Low service utilization is evident, and urologists play an integral role in reinforcing national health insurance utilization. For future studies, it is imperative that administrative and clinical data linkages are established to form a more holistic picture of the urologic disease burden in the country. A rethinking of process flows for case reporting may also be considered to avoid data loss from patients who are coded as 'procedure only' cases; analyzing ICD and RVS codes hand-in-hand may serve to mitigate this loss.

It is made available under a CC-BY-NC-ND 4.0 International license .

Acknowledgments

The information herein was owed in part to the expert opinion of the following individuals and their constituent institutions

Philippine Endourological Society

Philippine Society of Urologic Oncology

Dr. Bernadette Lico and Mr. Paulus Bacud of the Philippine Health Insurance Corporation – Corporate Planning Unit

References

- 1. Grossmann C, Institute of Medicine (U.S.). Roundtable on Value & Science-Driven Health Care. Clinical data as the basic staple of health learning : creating and protecting a public good : workshop summary. National Academies Press; 2010. 313 p.
- 2. Laudico AV, Medina V, Mapua C, Redaniel MT, Mirasol-lumague MR, Valenzuela FG, et al. Philippine Cancer Facts. Philippine Cancer Society- Manila Cancer Registry. 2010;1–48.
- 3. PhilHealth. Stats and Charts 2019. PhilHealth. 2019;
- 4. Hux, JE; Ivis, F; Flintoft, V; Bica A. Diabetes in Ontario. Diabetes Care. 2002;3:512-.
- 5. Rassen JA, Bartels DB, Schneeweiss S, Patrick AR, Murk W. Measuring prevalence and incidence of chronic conditions in claims and electronic health record databases. Clin Epidemiol. 2019;11:1–15.
- 6. Epping J, Geyer S, Tetzlaff J. The effects of different lookback periods on the sociodemographic structure of the study population and o1. Epping J, Geyer S, Tetzlaff J. The effects of different lookback periods on the sociodemographic structure of the study population and on the estim. BMC Med Res Methodol. 2020;20(1):1–15.
- Williams L. The Performance of Different Lookback Periods and Sources of Information for Charlson Comorbidity Adjustment in Medicare Claims Author (s): James X. Zhang, Theodore J. Iwashyna and Nicholas A. Christakis Published by : Lippincott Williams & Wilkins . 1999;37(11):1128–39.
- 8. Czwikla J, Jobski K, Schink T. The impact of the lookback period and definition of confirmatory events on the identification of incident cancer cases in administrative data. BMC Med Res Methodol. 2017;17(1):122.
- 9. Litwin MS, Saigal CS. Urologic Diseases in America National Institute of Diabetes and Digestive and Kidney Diseases. Review. 2012;551–62.
- Ng JYS, Ramadani RV, Hendrawan D, Duc DT, Kiet PHT. National Health Insurance Databases in Indonesia, Vietnam and the Philippines. Pharmacoecon Open [Internet]. 2019;3(4):517–26. Available from: https://doi.org/10.1007/s41669-019-0127-2
- 11. Esteban DB, Laudico A v., Uy NA, Benabay L. Cancer Registration in the Philippines. Asian Pacific Journal of Cancer Prevention. 2001;2(63 2):55–60.
- 12. Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. GLOBOCAN 2020 annexes. 2020;
- Bermudez-delos Santos AAA, Tumanan-Mendoza BA, Mendoza VL, Sison EOD, Punzalan FER, Pestano NS, et al. The Epidemiologic Burden of Hospitalization for Coronary Artery Disease Among Adults Aged 19 years and above in the Philippines. Philipp J Cardiol. 2020;(December):8–19.
- Philippine Health Insurance Corporation. All Case Rates (ACR) Policy No. 1 --- Governing Policies In The Shift Of Provider Payment Mechanism From Fee-For-Service To Case-Based Payment (Philhealth Circular 2013-No 0035) [Internet]. Manila; 2013 [cited 2022 Nov 6]. Available from: https://www.philhealth.gov.ph/circulars/2013/circ31 2013.pdf
- 15. Philippine Health Insurance Corporation. ACR Policy No. 2 --- Implementing Guidelines On Medical And Procedures Case Rates [Internet]. Philhealth Website. 2013 [cited 2022 Nov 6]. Available from: https://www.philhealth.gov.ph/circulars/2013/circ35_2013.pdf

Appendix A: Supplementary Tables

Supplementary Table 1. Prevalent Kidney Cancer Cases Per Year Based on Paid Claims Only, Within Period of Interest and Lookback	
Period	

	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
					F	requency					
Total	223	507	769	870	977	1,130	1,201	1,208	1,183	1,154	980
Age, years											
≤19	36	81	126	134	164	185	216	209	214	213	193
20-39 40-59 60-69	14 68 50	24 151 136	40 241 194	46 282 246	56 305 279	57 351 335	58 361 346	54 390 320	59 371 314	60 370 294	54 303 266
≥70	55	115	168	162	173	202	220	235	225	217	164
Sex											
Male	149	323	504	568	615	698	754	783	763	709	600
Female	74	184	265	302	362	432	447	425	420	445	380

Supplementary Table 2. Prevalent Kidney Cancer Cases Per Year Based on Filed Claims Within Period of Interest Alone (Without Lookback)

	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
					F	requency					
Total	229	321	300	330	420	469	437	433	458	406	318
Age, years											
≤19	37	52	50	48	90	83	87	77	90	94	84
20-39	14	11	17	21	22	18	22	19	24	23	16
40-59	70	95	106	110	113	151	128	146	141	121	99
60-69	52	97	68	100	122	129	122	102	120	100	82
≥70	56	66	59	51	73	88	78	89	83	68	37

	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
					F	requency					
Total	223	507	769	870	977	1,130	1,201	1,208	1,183	1,154	980
Age, years											
≤19	36	81	126	134	164	185	216	209	214	213	193
20-39	14	24	40	46	56	57	58	54	59	60	54
40-59	68	151	241	282	305	351	361	390	371	370	303
60-69	50	136	194	246	279	335	346	320	314	294	266
≥70	55	115	168	162	173	202	220	235	225	217	164
Sex											
Male	149	323	504	568	615	698	754	783	763	709	600
		404	265	302	362	432	447	425	420	445	380
Female Supplementary T	74 Table 2. Prevale	184 ent Kidney (200 Cancer Case	es Per Year	Based on F	iled Claims	Within Per	iod of Inter	est Alone (Without Lo	okback)
Female Supplementary T	74 able 2. Prevale 2011	184 ent Kidney (2012	Cancer Case 2013	es Per Year 2014	Based on F 2015	iled Claims 2016	Within Per 2017	iod of Inter 2018	rest Alone (2019	Without Loc 2020	okback) 2021
Female Supplementary T	74 Table 2. Prevale 2011	184 ent Kidney (2012	203 Cancer Case 2013	es Per Year 2014	Based on F 2015 F	iled Claims 2016 requency	Within Per 2017	iod of Inter 2018	rest Alone (2019	Without Loo 2020	okback) 2021
Female Supplementary T Male	74 Table 2. Preval e 2011 154	184 ent Kidney (2012 200	203 Cancer Case 2013 208	2014 219	Based on F 2015 237	iled Claims 2016 requency 294	Within Per 2017 300	iod of Inter 2018 278	rest Alone (2019 279	Without Loo 2020 243	okback) 2021
Female Supplementary T Male Female	74 Fable 2. Prevale 2011 154 75	184 ent Kidney (2012 200 121	203 Cancer Case 2013 208 92	2014 219 111	Based on F 2015 F 237 183	iled Claims 2016 requency 294 175	Within Per 2017 300 137	iod of Inter 2018 278 155	2019 279 179	Without Loo 2020 243 163	okback) 2021 186 132
Female Supplementary T Male Female Supplementary T	74 	184 ent Kidney (2012 200 121 t Kidney Ca	203 Cancer Case 2013 208 92 ncer Cases	2014 219 211 219 111 Per Year Ba	Based on F 2015 F 237 183 ased on Pai	iled Claims 2016 requency 294 175 d Claims Of	Within Per 2017 300 137 nly, Within	iod of Inter 2018 278 155 Period of In	rest Alone (2019 279 179 nterest	Without Loo 2020 243 163	okback) 2021 186 132
Female Supplementary T Male Female Supplementary T	74 Fable 2. Prevale 2011 154 75 Fable 3. Inciden 2011	184 ent Kidney (2012 200 121 t Kidney Ca 2012	203 Cancer Case 2013 208 92 ncer Cases 2013	2014 219 111 Per Year Ba 2014	Based on F 2015 F 237 183 ased on Pai 2015	iled Claims 2016 requency 294 175 d Claims Or 2016	Within Per 2017 300 137 nly, Within 2017	iod of Inter 2018 278 155 Period of In 2018	rest Alone (2019 279 179 nterest 2019	Without Loc 2020 243 163 2020	okback) 2021 186 132 2021
Female Supplementary T Male Female Supplementary T	74 Fable 2. Prevale 2011 154 75 Fable 3. Inciden 2011	184 ent Kidney (2012 200 121 t Kidney Ca 2012	203 Cancer Case 2013 208 92 ncer Cases 2013	2014 219 111 Per Year Ba 2014	Based on F 2015 7 237 183 ased on Pai 2015 F	iled Claims 2016 requency 294 175 d Claims Or 2016 requency	Within Per 2017 300 137 nly, Within 2017	iod of Inter 2018 278 155 Period of In 2018	rest Alone (2019 279 179 nterest 2019	Without Loo 2020 243 163 2020	okback) 2021 186 132 2021
Female Supplementary T Male Female Supplementary T Total	74 Fable 2. Prevale 2011 154 75 Fable 3. Inciden 2011 223	184 ent Kidney (200 121 t Kidney Ca 2012 284	203 Cancer Case 2013 208 92 ncer Cases 2013 262	2014 219 111 Per Year Ba 2014 295	Based on F 2015 F 237 183 ased on Pai 2015 F 387	iled Claims 2016 requency 294 175 d Claims Or 2016 requency 421	Within Per 2017 300 137 nly, Within 2017 375	iod of Inter 2018 278 155 Period of In 2018 374	rest Alone (2019 279 179 nterest 2019 385	Without Loo 2020 243 163 2020 350	okback) 2021 186 132 2021 210
Female Supplementary T Male Female Supplementary T Total Age, years	74 Fable 2. Prevale 2011 154 75 Fable 3. Inciden 2011 223	184 ent Kidney (200 121 t Kidney Ca 2012 284	203 Cancer Case 2013 208 92 ncer Cases 2013 262	2014 219 111 Per Year Ba 2014 295	Based on F 2015 F 237 183 ased on Pai 2015 F 387	iled Claims 2016 requency 294 175 d Claims Or 2016 requency 421	Within Per 2017 300 137 nly, Within 2017 375	iod of Inter 2018 278 155 Period of In 2018 374	rest Alone (2019 279 179 nterest 2019 385	Without Loo 2020 243 163 2020 350	okback) 2021 186 132 2021 210
Female Supplementary T Male Female Supplementary T Total Age, years ≤19	74 Table 2. Prevale 2011 154 75 Table 3. Inciden 2011 223 36	184 ent Kidney (200 121 t Kidney Ca 2012 284 45	203 Cancer Case 2013 208 92 ncer Cases 2013 262 45	2014 219 111 Per Year Ba 2014 295 38	Based on F 2015 F 237 183 ased on Pai 2015 F 387 77	iled Claims 2016 requency 294 175 d Claims Or 2016 requency 421	Within Per 2017 300 137 nly, Within 2017 375 69	iod of Inter 2018 278 155 Period of In 2018 374	rest Alone (2019 279 179 nterest 2019 385 67	Without Loo 2020 243 163 2020 350 72	2021 186 132 2021 2021 210
Female Supplementary T Male Female Supplementary T Total Age, years ≤19 20-39	74 Table 2. Prevale 2011 154 75 Table 3. Inciden 2011 223 36 14	184 ent Kidney (200 121 t Kidney Ca 2012 284 45 10	203 Cancer Case 2013 208 92 ncer Cases 2013 262 45 16	2014 219 111 Per Year Ba 2014 295 38 20	Based on F 2015 F 237 183 ased on Pai 2015 F 387 77 21	iled Claims 2016 requency 294 175 d Claims Or 2016 requency 421 64 15	Within Per 2017 300 137 nly, Within 2017 375 69 20	iod of Inter 2018 278 155 Period of In 2018 374 62 17	rest Alone (2019 279 179 nterest 2019 385 67 21	Without Loo 2020 243 163 2020 350 72 21	2021 186 132 2021 2021 2021 210

Supplementary Table 1. Prevalent Kidney Cancer Cases Per Year Based on Paid Claims Only, Within Period of Interest and Lookback Period

/											
	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
					F	requency					
60-69	50	85	58	94	115	121	108	88	108	90	60
≥70	55	59	53	43	70	81	66	77	72	58	28
Sex											
Male Female	149 74	174 110	181 81	194 101	218 169	268 153	259 116	236 138	233 152	209 141	133 77

Supplementary Table 4. Kidney Cancer Prevalence, Incidence Across Years

Year	Total	Prevalence of filed claims (95% CI)	Prevalence of paid claims (95% CI)	Incidence of filed claims (95% CI)	Incidence of paid claims (95% CI)
	beneficiaries				
2011	78,390,000	0.0000029 (0.0000026-0.0000033)	0.0000028 (0.0000025-0.0000032)	0.0000029 (0.0000026-0.0000033)	0.0000028 (0.0000025-0.0000032)
2012	80,920,000	0.0000064 (0.0000059-0.000007)	0.0000063 (0.0000057-0.0000068)	0.0000036 (0.0000032-0.000004)	0.0000035 (0.0000031-0.0000039)
2013	76,900,000	0.00001 (0.0000096-0.000011)	0.00001 (0.0000093-0.000011)	0.0000035 (0.0000031-0.0000039)	0.0000034 (0.000003-0.0000039)
2014	86,224,256	0.00001 (0.0000096-0.000011)	0.00001 (0.0000094-0.000011)	0.0000035 (0.0000031-0.0000039)	0.0000034 (0.000003-0.0000038)
2015	93,445,053	0.000011 (0.00001-0.000011)	0.000011 (0.0000098-0.000011)	0.0000042 (0.0000038-0.0000047)	0.0000041 (0.0000037-0.0000046)
2016	93,400,861	0.000012 (0.000012-0.000013)	0.000012 (0.000011-0.000013)	0.0000045 (0.0000041-0.000005)	0.0000045 (0.0000041-0.000005)
2017	96,973,681	0.000013 (0.000012-0.000013)	0.000012 (0.000012-0.000013)	0.000004 (0.0000036-0.0000044)	0.0000039 (0.0000035-0.0000043)
2018	104,488,979	0.000012 (0.000011-0.000013)	0.000012 (0.000011-0.000012)	0.0000037 (0.0000034-0.0000041)	0.0000036 (0.0000032-0.000004)
2019	97,750,573	0.000013 (0.000012-0.000014)	0.000012 (0.000011-0.000013)	0.0000043 (0.0000039-0.0000047)	0.0000039 (0.0000036-0.0000044)
2020	95,999,756	0.000013 (0.000012-0.000014)	0.000012 (0.000011-0.000013)	0.0000039 (0.0000035-0.0000043)	0.0000037 (0.0000033-0.0000041)
2021	98,030,269	0.000011 (0.000011-0.000012)	0.00001 (0.0000094-0.000011)	0.0000029 (0.0000026-0.0000033)	0.0000021 (0.0000019-0.0000025)

Supplementary Table 5. Prevalent Bladder Cancer Cases Per Year Based on Paid Claims Only Within Period of Interest and Lookback Period

•• •											
	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
					F	Frequency					
Total	191	364	562	637	760	913	992	1,026	1,006	893	733
Age, years											
≤19	2	2	3	6	13	16	13	9	5	7	7
20-39	5	9	18	23	38	42	41	33	31	31	24
40-59	46	90	139	150	172	202	222	226	224	206	185
60-69	52	98	150	182	210	274	297	324	316	294	250

	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
					F	requency					
≥70	86	165	252	276	327	379	419	434	430	355	267
Sex											
Male	137	264	399	449	538	647	695	701	691	623	518
Female	54	100	163	188	222	266	297	325	315	270	215
Cancer subtype (not mutually											
exclusive)											
Malignant neoplasm of anterior wall of bladder	2	0	1	3	2	3	1	2	2	1	1
Malignant neoplasm of bladder	3	5	2	6	6	4	3	4	3	2	5
neck; maignant neoplasm of internal urethral orifice											
Malignant neoplasm of bladder,	180	181	215	236	274	334	342	302	318	237	138
unspecified											
Malignant neoplasm of dome of bladder	1	0	1	3	2	5	2	0	3	1	2
Malignant neoplasm of lateral wall of bladder	1	0	1	4	1	6	3	6	4	3	3
Malignant neoplasm of	3	1	0	4	2	0	2	3	3	1	1
overlapping lesion of bladder											
Malignant neoplasm of posterior wall of bladder	1	0	0	0	0	0	0	0	0	0	0
Malignant neoplasm of trigone	3	1	1	18	13	14	14	5	13	9	7
of bladder											
Malignant neoplasm of urachus	2	1	2	1	2	2	1	3	3	3	1
Malignant neoplasm of ureteric orifice	0	2	4	0	0	2	1	2	5	2	3

Supplementary Table 5. Prevalent Bladder Cancer Cases Per Year Based on Paid Claims Only Within Period of Interest and Lookback Period

Supplementary Table 6. Prevalent Bladder Cancer Cases Per Year Based on Filed Claims Within Period of Interest Along (Without Lookback Period)

-											
	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
					F	requency					
Total	202	201	225	270	308	373	378	345	371	280	209

Age, years

	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
					F	requency					
≤19	2	1	1	4	11	6	2	2	1	4	4
20-39	6	4	11	11	19	13	10	12	13	10	7
40-59	47	53	58	56	68	84	87	75	87	67	61
60-69	56	57	58	87	79	120	114	109	120	96	72
≥70	91	86	97	112	131	150	165	147	150	103	65
Sex											
Male	143	150	157	189	222	262	255	230	270	196	133
Female	59	51	68	81	86	111	123	115	101	84	76
Cancer subtype											
Malignant neoplasm of anterior wall of bladder	2	0	1	3	2	3	1	2	2	2	1
Malignant neoplasm of bladder neck; malignant neoplasm of internal urethral orifice	3	5	2	6	6	6	3	4	3	2	5
Malignant neoplasm of bladder, unspecified	190	194	221	240	285	341	354	322	342	258	179
Malignant neoplasm of dome of bladder	1	0	1	4	2	5	2	0	3	1	2
Malignant neoplasm of lateral wall of bladder	1	0	1	4	1	6	3	6	5	3	5
Malignant neoplasm of overlapping lesion of bladder	3	1	0	4	3	0	2	3	3	1	1
Malignant neoplasm of posterior wall of bladder	2	0	0	0	0	0	0	0	0	0	0
Malignant neoplasm of trigone of bladder	3	1	2	18	13	14	14	5	15	12	13
Malignant neoplasm of urachus	2	1	2	1	2	2	1	3	3	4	1
Malignant neoplasm of ureteric orifice	0	2	4	0	0	2	1	2	5	2	7

Supplementary Table 6. Prevalent Bladder Cancer Cases Per Year Based on Filed Claims Within Period of Interest Along (Without Lookback Period)

	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
						Frequency					
Total	196	176	205	257	295	362	343	318	335	242	149
Age, years	•	•						•			
≤19	2	0	1	4	8	4	1	2	1	4	2
20-39	5	4	9	10	18	13	10	10	11	7	5
40-59	46	44	49	50	66	80	76	66	75	61	44
60-69	52	46	52	80	73	116	107	100	108	84	53
≥70	86	79	87	106	125	143	146	138	130	82	42
Sex											
Male	137	127	135	175	211	250	230	211	235	168	97
Female	54	46	63	75	79	106	110	105	90	70	49
Cancer subtype											
Malignant neoplasm of anterior wall of bladder	2	0	1	3	2	3	1	2	2	1	1
Malignant neoplasm of bladder neck; malignant neoplasm of	3	5	2	6	6	4	3	4	3	2	5
internal urethral orifice											
Malignant neoplasm of bladder, unspecified	180	166	194	218	267	326	316	293	299	223	127
Malignant neoplasm of dome of	1	0	1	3	2	5	2	0	3	1	2
Malignant neoplasm of lateral	1	0	1	4	1	6	3	6	4	3	3
wall of bladder											
Malignant neoplasm of	3	1	0	4	2	0	2	3	3	1	1
overlapping lesion of bladder	1	0	0	0	٥	0	٥	0	0	0	٥
wall of bladder	I	0	U	U	U	0	U	U	U	U	0
Malignant neoplasm of trigone of bladder	3	1	1	18	13	14	14	5	13	8	7
Malignant neoplasm of urachus	2	1	1	1	2	2	1	3	3	1	0
Malignant neoplasm of ureteric orifice	0	2	4	0	0	2	1	2	5	2	3

Supplementary Table 7. Incident Bladder Cancer Cases Per Year Based on Paid Claims Only, Within Period	of Interest and Lookback Per	riod
--	------------------------------	------

Year	Total	Prevalence of filed claims (95% CI)	Prevalence of paid claims (95% CI)	Incidence of filed claims (95% CI)	Incidence of paid claims (95% CI)
	beneficiaries				
2011	78,390,000	0.0000026 (0.0000022-0.000003)	0.0000024 (0.0000021-0.0000028)	0.0000026 (0.0000022-0.000003)	0.0000024 (0.0000021-0.0000028)
2012	80,920,000	0.0000048 (0.0000043-0.0000053)	0.0000045 (0.0000041-0.000005)	0.0000023 (0.000002-0.0000027)	0.0000021 (0.0000018-0.0000025)
2013	76,900,000	0.0000077 (0.0000071-0.0000084)	0.0000073 (0.000067-0.0000079)	0.0000027 (0.0000023-0.0000031)	0.0000026 (0.0000022-0.000003)
2014	86,224,256	0.0000077 (0.0000071-0.0000083)	0.0000074 (0.0000068-0.000008)	0.000003 (0.0000026-0.0000033)	0.0000029 (0.0000026-0.0000033)
2015	93,445,053	0.0000083 (0.0000078-0.0000089)	0.0000081 (0.0000076-0.0000087)	0.0000032 (0.0000028-0.0000036)	0.0000031 (0.0000028-0.0000035)
2016	93,400,861	0.00001 (0.0000094-0.000011)	0.0000098 (0.0000092-0.00001)	0.0000039 (0.0000035-0.0000043)	0.0000038 (0.0000034-0.0000042)
2017	96,973,681	0.000011 (0.0000099-0.000011)	0.00001 (0.0000096-0.000011)	0.0000036 (0.0000032-0.000004)	0.0000035 (0.0000031-0.0000039)
2018	104,488,979	0.00001 (0.0000096-0.000011)	0.0000098 (0.0000092-0.00001)	0.0000032 (0.0000028-0.0000035)	0.000003 (0.0000027-0.0000034)
2019	97,750,573	0.000011 (0.00001-0.000012)	0.00001 (0.0000097-0.000011)	0.0000036 (0.0000032-0.000004)	0.0000033 (0.000003-0.0000037)
2020	95,999,756	0.00001 (0.0000094–0.000011)	0.0000093 (0.000087-0.0000099)	0.0000027 (0.0000024-0.0000031)	0.0000025 (0.0000022-0.0000028)
2021	98,030,269	0.0000085 (0.0000079–0.0000091)	0.0000075 (0.000007-0.000008)	0.000002 (0.0000017-0.0000023)	0.0000015 (0.0000013-0.0000018)

Supplementary Table 8. Bladder Cancer Prevalence, Incidence Across Years

Supplementary Table 9. Prevalent Testicular Cancer Cases Per Year Based on Paid Claims Only, Within Period of Interest and Lookback Period

	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
					F	requency					
Total	61	130	192	231	281	328	387	425	432	409	358
Age, years											
≤19	15	32	44	60	73	96	116	120	121	116	104
20-39	30	58	82	87	109	133	155	183	174	174	152
40-59	14	35	53	62	70	69	81	79	92	83	80
60-69	2	4	9	13	18	19	19	23	22	21	13
≥70	-	1	4	9	11	11	16	20	23	15	9

Supplementary Table 10. Prevalent Testicular Cancer Cases Per Year Based on Filed Claims Within Period of Interest Alone (Without Lookback)

_	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
					Fi	requency					
Total	63	78	75	100	123	124	169	176	146	142	141

Age, years

=====											
	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
					F	requency					
≤19	15	20	16	31	32	37	57	47	43	51	48
20-39	31	33	30	35	52	59	61	80	58	56	65
40-59	14	22	20	23	30	18	35	29	33	28	25
60-69	3	2	6	6	6	7	6	12	6	5	2
≥70	-	1	3	5	3	3	10	8	6	2	1

Supplementary Table 10. Prevalent Testicular Cancer Cases Per Year Based on Filed Claims Within Period of Interest Alone (Without Lookback)

Supplementary Table 11. Incident Testicular Cancer Cases Per Year Based on Paid Claims Only, Within Period of Interest

	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
					F	requency					
Total	61	69	62	92	115	116	151	149	119	124	104
Age, years											
≤19	15	17	12	28	29	37	48	35	31	41	29
20-39	30	28	24	31	49	52	53	71	45	53	49
40-59	14	21	18	22	28	17	34	26	31	23	23
60-69	2	2	5	6	6	7	6	10	6	5	2
≥70	-	1	3	5	3	3	10	7	6	2	1

Supplementary Table 12. Testicular Cancer Prevalence Across Years

Year	Total beneficiaries	Prevalence of filed claims (95% CI)	Prevalence of paid claims (95% CI)
2011	14,702,032	0.00000429 (0.00000329–0.00000548)	0.00000415 (0.00000317-0.00000533)
2012	15,834,192	0.0000084 (0.00000703-0.00000995)	0.00000821 (0.00000686-0.00000975)
2013	16,945,352	0.0000116 (0.00001-0.0000133)	0.0000113 (0.00000978-0.0000131)
2014	44,403,501	0.00000529 (0.00000464-0.00000601)	0.0000052 (0.00000455-0.00000592)
2015	47,814,214	0.00000598 (0.00000531-0.00000672)	0.00000588 (0.00000521-0.00000661)
2016	47,960,271	0.00000692 (0.0000062-0.00000771)	0.00000684 (0.00000612-0.00000762)
2017	46,307,729	0.00000847 (0.00000765-0.00000935)	0.00000836 (0.00000755-0.00000923)
2018	51,486,361	0.00000851 (0.00000773–0.00000934)	0.00000825 (0.00000749-0.00000908)
2019	46,681,095	0.00000988 (0.00000899–0.0000108)	0.00000925 (0.0000084–0.0000102)
2020	46,024,677	0.00000956 (0.00000869–0.0000105)	0.00000889 (0.00000805–0.00000979)
2021	45,746,463	0.00000879 (0.00000795-0.00000969)	0.00000783 (0.00000704-0.00000868)

	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
					F	requency					
Total	11	26	44	58	75	82	89	84	97	96	76
Age, years											
≤19	-	-	-	-	-	-	-	-	-	-	-
20-39	3	3	6	8	11	10	11	10	13	15	13
40-59	5	12	23	32	42	43	46	47	52	53	40
60-69	1	5	7	9	13	14	18	14	20	16	13
≥70	2	6	8	9	9	15	14	13	12	12	10

Supplementary Table 13. Prevalent Penile Cancer Cases Per Year Based on Paid Claims Only, Within Period of Interest and Lookback Period

Supplementary Table 14. Prevalent Penile Cancer Cases Per Year Based on Filed Claims Within Period of Interest Alone (Without Lookback)

	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
					F	requency					
Total	12	18	23	24	31	28	32	30	40	33	18
Age, years											
≤19	-	-	-	-	-	-	-	-	-	-	-
20-39	3	1	3	4	4	2	6	3	5	8	2
40-59	5	9	14	14	17	13	17	18	17	20	11
60-69	1	4	4	3	6	5	7	4	10	3	4
≥70	3	4	2	3	4	8	2	5	8	2	1

Supplementary Table 15. Incident Penile Cancer Cases Per Year Based on Paid Claims Only, Within Period of Interest

/											
	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
					F	requency					
Total	11	15	18	23	30	28	30	26	38	30	8
Age, years											
≤19	-	-	-	-	-	-	-	-	-	-	-
20-39	3	-	3	4	4	2	5	3	4	8	1

•• •	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
					F	requency					
40-59	5	7	11	13	16	13	16	18	17	18	5
60-69	1	4	2	3	6	5	7	2	10	2	1
≥70	2	4	2	3	4	8	2	3	7	2	1

Supplementary Table 15. Incident Penile Cancer Cases Per Year Based on Paid Claims Only, Within Period of Interest

Supplementary Table 16. Penile Cancer Prevalence Across Years

Year	Total beneficiaries	Prevalence of filed claims (95% CI)	Prevalence of paid claims (95% CI)
2011	14,702,032	0.000000816 (0.000000422-0.00000143)	0.000000748 (0.000000373-0.00000134)
2012	15,834,192	0.00000177 (0.00000118-0.00000256)	0.00000164 (0.00000107-0.00000241)
2013	16,945,352	0.00000277 (0.00000204-0.00000369)	0.0000026 (0.00000189-0.00000349)
2014	44,403,501	0.00000135 (0.00000103-0.00000174)	0.00000131 (0.000000992-0.00000169)
2015	47,814,214	0.00000159 (0.00000125-0.00000199)	0.00000157 (0.00000123-0.00000197)
2016	47,960,271	0.00000171 (0.00000136-0.00000212)	0.00000171 (0.00000136-0.00000212)
2017	46,307,729	0.00000192 (0.00000154-0.00000237)	0.00000192 (0.00000154-0.00000237)
2018	51,486,361	0.00000163 (0.0000013-0.00000202)	0.00000163 (0.0000013-0.00000202)
2019	46,681,095	0.00000212 (0.00000172-0.00000258)	0.00000208 (0.00000169-0.00000253)
2020	46,024,677	0.00000217 (0.00000177–0.00000264)	0.00000209 (0.00000169-0.00000255)
2021	45,746,463	0.00000192 (0.00000154–0.00000237)	0.00000166 (0.00000131-0.00000208)

Supplementary Table 17. Prevalent Prostate Cancer Cases Per Year Based on Paid Claims Only Within Period of Interest and Lookback Period

	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
					F	requency					
Total	835	1,657	2,446	2,611	2,965	3,348	3,620	3,765	3,771	3,486	2,844
Age, years											
≤19	1	4	6	8	6	3	3	1	1	1	1
20-39	6	11	14	9	7	3	6	5	6	4	5
40-59	74	144	221	241	255	272	280	310	308	314	261
60-69	238	473	729	770	881	964	1,072	1,113	1,133	1,051	882
≥70	516	1,025	1,476	1,583	1,816	2,106	2,259	2,336	2,323	2,116	1,695

	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
					F	requency					
No	793	1,496	2,168	2,384	2,837	3,339	3,615	3,752	3,754	3,466	2,832
Yes	42	161	278	227	128	9	5	13	17	20	12
Region											
NCR	236	493	745	790	818	842	865	915	898	765	556
I – Ilocos	58	110	174	195	236	260	282	283	322	322	291
II – Cagayan	35	56	86	83	110	126	145	149	147	157	134
III – Central Luzon	73	150	223	232	251	276	317	341	343	321	246
IV-A - CALABARZON	46	85	122	128	155	184	202	205	217	191	170
IV-B – MIMAROPA	37	72	111	119	140	156	169	178	177	170	143
V – BICOL	27	47	68	70	96	123	133	137	140	153	140
VI – Western Visayas	79	149	191	197	228	276	301	308	319	315	281
VII – Central Visayas	106	207	297	279	288	318	342	366	341	323	261
VIII – Eastern	7	21	32	47	68	91	107	121	129	124	93
Visayas											
IX – Zamboanga	13	29	36	57	65	86	91	90	91	73	60
Peninsula											
X – Northern	27	50	80	102	145	183	193	191	192	177	142
Mindanao											
XI – Davao Region	48	86	126	140	164	186	173	180	167	147	104
XII - Soccsksargen	18	43	67	69	90	108	143	153	155	136	120
CAR	16	42	65	74	74	85	108	107	94	73	64
ARMM	-	1	2	4	4	3	2	1	2	3	3
CARAGA	8	13	18	21	32	43	45	37	35	34	36
UNKNOWN	1	3	3	4	1	2	2	3	2	2	-
Class											
Ambulatory surgical	-	-	9	8	8	1	-	-	-	-	-
clinic											
Infirmary / dispensary	10	23	41	34	23	13	24	28	24	14	8
Level 1	124	233	359	402	494	574	641	645	655	659	604
Level 2	269	499	722	803	1,021	1,239	1,355	1,402	1,407	1,323	1,126

Supplementary Table 17. Prevalent Prostate Cancer Cases Per Year Based on Paid Claims Only Within Period of Interest and Lookback Period

Supplementary Table 17. Prevalent Prostate Cancer Cases Per Year Based on Paid Claims Only Within Period of Interest and Lookback Period

	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
					F	requency					
Level 3	431	899	1,312	1,360	1,418	1,519	1,598	1,687	1,683	1,488	1,106
Unknown	1	3	3	4	1	2	2	3	2	2	-

Supplementary Table 18. Prevalent Prostate Cancer Cases Per Year Based on Filed Claims Within Period of Interest Along (Without Lookback Period)

/	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
					F	requency					
Total	874	921	945	1,042	1,252	1,351	1,406	1,446	1,409	1,056	742
Age, years											
≤19	1	4	3	2	2	-	1	-	1	1	-
20-39	7	6	6	-	3	1	4	1	2	1	2
40-59	79	83	92	99	97	102	114	128	109	117	72
60-69	252	262	306	299	363	398	440	433	429	336	251
≥70	535	566	538	642	787	850	847	884	868	601	417
Outpatient											
No	824	789	795	1,037	1,247	1,346	1,404	1,433	1,402	1,051	739
Yes	50	132	150	5	5	5	2	13	7	5	3
Region											
NCR	253	293	316	297	303	335	351	370	344	201	147
I – Ilocos	58	57	70	83	97	102	114	99	139	116	65
II – Cagayan	38	27	34	29	54	51	52	62	55	60	32
III – Central Luzon	77	84	84	84	103	110	129	136	117	98	59
IV-A - CALABARZON	46	42	42	53	68	76	73	79	86	45	53
IV-B – MIMAROPA	38	42	46	45	63	60	60	74	66	49	43
V – BICOL	27	21	23	32	48	50	46	55	50	60	39
VI – Western Visayas	79	77	55	85	105	111	127	111	136	112	71
VII – Central Visayas	110	112	112	97	116	145	124	137	121	93	77

	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
					F	requency					
VIII – Eastern	7	14	11	23	39	37	39	56	45	38	26
Visayas											
IX – Zamboanga	14	17	8	33	26	33	41	26	28	20	12
Peninsula											
X – Northern	28	23	34	52	72	74	67	76	68	48	38
Mindanao											
XI – Davao Region	51	42	46	68	63	63	58	69	53	38	19
XII - Soccsksargen	18	25	26	24	46	47	64	54	51	43	32
CAR	18	35	31	22	30	40	47	28	32	22	17
ARMM	-	1	1	2	1	-	1	-	1	2	-
CARAGA	8	5	5	12	17	16	13	11	17	11	12
UNKNOWN	4	4	1	1	1	1	-	3	-	-	-
Ambulatory surgical	_	-	Q	1	-	1	-	1	-	-	_
clinic			0	I		I		I			
Infirmary / dispensary	11	13	18	3	4	8	13	9	4	3	1
Level 1	131	120	142	181	210	219	256	236	243	241	181
Level 2	279	258	263	355	477	502	513	532	525	413	313
Level 3	449	526	512	501	560	620	624	665	637	399	247
Unknown	4	4	1	1	1	1	-	3	-	-	

Supplementary Table 18. Prevalent Prostate Cancer Cases Per Year Based on Filed Claims Within Period of Interest Along (Without Lookback Period)

Supplementary Table 19. Incident Prostate Cancer Cases Per Year Based on Paid Claims Only, Within Period of Interest and Lookback Period

	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
					F	requency					
Total	835	822	789	919	1,132	1,189	1,203	1,216	1,168	918	605
Age, years											
≤19	1	3	2	2	2	0	1	0	0	1	0
20-39	6	3	5	0	2	0	3	1	2	1	2

	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
					F	requency					
40-59	74	71	76	88	84	93	100	115	89	106	57
60-69	238	237	260	258	326	346	374	350	352	289	199
≥70	516	508	446	571	718	750	725	750	725	521	347
Outpatient											
No	793	706	674	916	1.130	1,188	1.202	1.207	1.163	915	603
Yes	42	116	115	3	2	1	1	9	5	3	2
Region											
ŇĊR	236	254	254	266	258	288	286	302	262	157	107
I – Ilocos	58	54	64	73	90	89	98	86	124	102	53
II – Cagayan	35	22	29	23	50	48	46	51	42	52	29
III – Central Luzon	73	77	73	74	96	101	115	117	99	89	46
IV-A - CALABARZON	46	39	35	49	65	66	68	67	75	38	48
IV-B – MIMAROPA	37	35	36	38	57	54	53	59	55	43	38
V – BICOL	27	20	21	28	46	46	40	44	46	55	34
VI – Western Visayas	79	70	44	77	94	96	103	91	107	99	59
VII – Central Visayas	106	101	92	77	103	123	102	120	100	85	59
VIII – Eastern	7	13	11	22	35	33	35	48	41	28	19
Visayas											
IX – Zamboanga	13	16	6	33	24	28	35	21	27	19	12
Peninsula											
X – Northern	27	23	29	47	65	66	59	64	62	45	31
Mindanao											
XI – Davao Region	48	39	40	60	61	60	51	64	44	35	16
XII - Soccsksargen	18	25	25	18	43	39	59	47	44	39	30
CAR	16	26	24	20	27	36	41	24	25	20	13
ARMM	-	1	1	2	1	-	1	-	1	2	-
CARAGA	8	5	5	11	16	15	11	9	14	10	11
UNKNOWN	1	2	-	1	1	1	-	2	-	-	-

Supplementary Table 19. Incident Prostate Cancer Cases Per Year Based on Paid Claims Only, Within Period of Interest and Lookback Period

	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
					F	requency					
Ambulatory surgical clinic	-	-	9	1	-	-	-	-	-	-	-
Infirmary / dispensary	10	11	17	2	3	7	12	7	4	3	1
Level 1	124	108	127	153	197	197	223	197	204	218	148
Level 2	269	235	219	321	437	439	444	448	442	363	265
Level 3	431	466	417	441	494	545	524	562	518	334	191
Unknown	1	2	-	1	1	1	-	2	-	-	-

Supplementary Table 19. Incident Prostate Cancer Cases Per Year Based on Paid Claims Only, Within Period of Interest and Lookback Period

Supplementary Table 20. Prostate Cancer Prevalence Across Years

Year	Total beneficiaries	Prevalence of filed claims (95% CI)	Prevalence of paid claims (95% CI)
2011	14,702,032	0.0000594 (0.0000556-0.0000635)	0.0000568 (0.000053-0.0000608)
2012	15,834,192	0.0001084 (0.0001034–0.0001137)	0.0001046 (0.0000997-0.0001098)
2013	16,945,352	0.0001493 (0.0001435-0.0001552)	0.0001443 (0.0001387-0.0001502)
2014	44,403,501	0.0000603 (0.000058-0.0000626)	0.0000588 (0.0000566-0.0000611)
2015	47,814,214	0.0000634 (0.0000612-0.0000657)	0.000062 (0.0000598-0.0000643)
2016	47,960,271	0.0000709 (0.0000685–0.0000733)	0.0000698 (0.0000675-0.0000722)
2017	46,307,729	0.0000796 (0.000077-0.0000822)	0.0000782 (0.0000756-0.0000808)
2018	51,486,361	0.0000749 (0.0000725-0.0000773)	0.0000731 (0.0000708-0.0000755)
2019	46,681,095	0.0000841 (0.0000815–0.0000868)	0.0000808 (0.0000782–0.0000834)
2020	46,024,677	0.0000792 (0.0000767–0.0000818)	0.0000757 (0.0000732–0.0000783)
2021	45,746,463	0.0000659 (0.0000636–0.0000683)	0.0000622 (0.0000599–0.0000645)